Funding round brings in $20M for Alzheimer's drug developer

05/24/2013 | MedCityNews.com

Acumen Pharmaceuticals has pulled in $20 million in a Series A funding round from BVF Partners, NeuroVentures Fund and other investors. Proceeds will go toward preclinical development of the firm's Alzheimer's disease drug candidate, an antibody that targets soluble oligomers of the amyloid beta peptide in the brain.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA